Table 2. Treatment arms, dose, frequency and administration route.

Cisplatin + PI3K-mTOR inhibitor experiment
Model	Drug	Dose	Frequency	Route
LADC 1 TNBC LGSOC	Cisplatin	3 mg / kg	Weekly	IP
	PF-05212384	10 mg/ Kg	2 times / week	IV
	Cisplatin	3 mg / kg	weekly	IP
	PF-05212384	10 mg/ Kg	2 times / week	IV
	Vehicle		weekly	IP
			2 times / week	+ IV
Paclitaxel + PI3K-mTOR inhibitor experiment
Model	Drug	Dose	Frequency	Route
LADC	Paclitaxel	15 mg / kg 2	2 times / week	IP
	PF-04691502	5 mg / kg	daily	PO
	Paclitaxel	15 mg / kg	2 times / week	IP
	PF-04691502	5 mg / kg	daily	PO
	Vehicle		daily	PO +
			2 times / week	IP
TNBC LGSOC	Paclitaxel	10 mg / kg	2 times / week	IP
	PF-05212384	10 mg / kg	2 times / week	IV
	Paclitaxel +	10 mg / kg	2 times / week	IP
	PF-05212384	10 mg / Kg	2 times / week	IV
	Vehicle		2 times / week	IP + IV
Dacomitinib + PI3K-mTOR inhibitor
Model	Drug	Dose	Frequency	Route
LADC	Dacomitinib	3 mg / kg	daily	PO
	PF-04691502	5 mg / kg	daily	PO
	Dacomitinib	3 mg / kg	daily	PO
	PF-04691502	5 mg / kg	daily	PO
	Vehicle		daily	PO
TNBC LGSOC	Dacomitinib	3 mg / Kg	daily	PO
	PF-05212384	10 mg/ Kg	2 times / week	IV
	Dacomitinib	3 mg / Kg	daily	PO
	PF-05212384	10 mg/ Kg	2 times / week	IV
	Vehicle		daily	PO
			2 times / week	IV

LADC: non-small cell lung cancer; TNBC: triple negative breast cancer; LGSOC: low-grade serous ovarian cancer; IP: intraperitoneal; IV: intravenous; PO: oral gavage; ¹ In the LADC model, PF-05212384 at a dose of 15 mg / kg was initially tested. Several sudden deaths occur after the first drug administration; thus, PF-05212384 was reduced to 10 mg / kg in subsequent administrations. The models evaluated afterwards (TNBC and LGOSC) received a dose of 10 mg / kg. ² Paclitaxel was initially evaluated at a dose of 15 mg / kg in the LADC and subsequently changed to 10 mg/kg based on several unexpected deaths in the paclitaxel-containing arms. Paclitaxel was tested at a dose of 10 mg / kg in the remaining models.